Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:200389rdf:typepubmed:Citationlld:pubmed
pubmed-article:200389lifeskim:mentionsumls-concept:C0080103lld:lifeskim
pubmed-article:200389lifeskim:mentionsumls-concept:C0228174lld:lifeskim
pubmed-article:200389lifeskim:mentionsumls-concept:C0043325lld:lifeskim
pubmed-article:200389lifeskim:mentionsumls-concept:C0238052lld:lifeskim
pubmed-article:200389pubmed:issue4lld:pubmed
pubmed-article:200389pubmed:dateCreated1978-1-27lld:pubmed
pubmed-article:200389pubmed:abstractTextA synopsis is given of 37 reported patients with cerebrotendinous xanthomatosis; divided in 11 possible, but not proven cases of C.T.Ch (cerebrotendinous cholestanolosis), and 26 proven cases. An increased content of cholestanol in serum or tissue, was used as the main criterion. The ophthalmological and neurological signs are tabulated. Attention is drawn to the fact that cholestanol is not mentioned in the extensive literature on related diseases with possible cerebrospinal xanthomas, such as eosinophilic granulomatosis and hyperlipoproteinemia. The importance of a possible role of cholestanol in these diseases is stressed. A hypothetical form of cerebrotendinous cholesterolosis is discussed. A family with a sibship of parents and twelve children, three of which showed C.T.Ch is described. The development of the clinical picture confirmed the variable expression of the autosomal recessive disease. Two patients showed disturbances of steroid metabolism. A first contribution to the search for linkage with the H.L.A. system is presented. Cholestanol over cholesterol ratio, appeared to be independent of the type of lipoprotein. In search for therapy we found in patients with hyperlipoproteinemia type II A, that cholestyramine alone gave dangerously high blood levels of cholestanol; in combined treatment of cholestyramine with clofibrate cholestanol, levels were comparable to those of the controls. The possibilities of therapy are discussed.lld:pubmed
pubmed-article:200389pubmed:languageenglld:pubmed
pubmed-article:200389pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:200389pubmed:citationSubsetIMlld:pubmed
pubmed-article:200389pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:200389pubmed:statusMEDLINElld:pubmed
pubmed-article:200389pubmed:issn0303-8467lld:pubmed
pubmed-article:200389pubmed:authorpubmed-author:van GentC MCMlld:pubmed
pubmed-article:200389pubmed:authorpubmed-author:DellemanJ WJWlld:pubmed
pubmed-article:200389pubmed:authorpubmed-author:de JongJ GJGlld:pubmed
pubmed-article:200389pubmed:issnTypePrintlld:pubmed
pubmed-article:200389pubmed:volume79lld:pubmed
pubmed-article:200389pubmed:ownerNLMlld:pubmed
pubmed-article:200389pubmed:authorsCompleteYlld:pubmed
pubmed-article:200389pubmed:pagination253-72lld:pubmed
pubmed-article:200389pubmed:dateRevised2009-10-14lld:pubmed
pubmed-article:200389pubmed:meshHeadingpubmed-meshheading:200389-H...lld:pubmed
pubmed-article:200389pubmed:meshHeadingpubmed-meshheading:200389-X...lld:pubmed
pubmed-article:200389pubmed:meshHeadingpubmed-meshheading:200389-B...lld:pubmed
pubmed-article:200389pubmed:meshHeadingpubmed-meshheading:200389-T...lld:pubmed
pubmed-article:200389pubmed:meshHeadingpubmed-meshheading:200389-F...lld:pubmed
pubmed-article:200389pubmed:meshHeadingpubmed-meshheading:200389-M...lld:pubmed
pubmed-article:200389pubmed:meshHeadingpubmed-meshheading:200389-S...lld:pubmed
pubmed-article:200389pubmed:meshHeadingpubmed-meshheading:200389-A...lld:pubmed
pubmed-article:200389pubmed:meshHeadingpubmed-meshheading:200389-P...lld:pubmed
pubmed-article:200389pubmed:meshHeadingpubmed-meshheading:200389-M...lld:pubmed
pubmed-article:200389pubmed:meshHeadingpubmed-meshheading:200389-C...lld:pubmed
pubmed-article:200389pubmed:year1977lld:pubmed
pubmed-article:200389pubmed:articleTitleCerebrotendinous cholestanolosis in relation to other cerebral xanthomatoses.lld:pubmed
pubmed-article:200389pubmed:publicationTypeJournal Articlelld:pubmed